Phase 1 study of the anti-BCMA antibody-drug conjugate AMG 224 in patients with relapsed/refractory multiple myeloma

被引：0
|
作者：
Hans C. Lee
Noopur S. Raje
Ola Landgren
Vijay V. Upreti
Jin Wang
Ariel A. Avilion
Xuguang Hu
Erik Rasmussen
Gataree Ngarmchamnanrith
Hisaki Fujii
Andrew Spencer
机构：
[1] The University of Texas MD Anderson Cancer Center,Department of Lymphoma/Myeloma
[2] Harvard Medical School,Center for Multiple Myeloma, Massachusetts General Hospital
[3] Memorial Sloan Kettering Cancer Center,Myeloma Service, Department of Medicine
[4] Amgen Inc.,Clinical Pharmacology Modeling & Simulation
[5] Amgen Inc.,Bioanalytical Sciences
[6] Amgen Inc.,Clinical Biomarkers & Diagnostics
[7] Amgen Inc.,Global Biostatistical Science
[8] Amgen Inc.,Clinical Development
[9] Amgen Inc.,Translational Medicine
[10] Monash University,Malignant Haematology & Stem Cell Transplantation Service, The Alfred Hospital
来源：
Leukemia | 2021年 / 35卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：255 / 258
页数：3
相关论文
共 50 条
  • [1] Letter phase 1 study of the anti-BCMA antibody-drug conjugate AMG 224 in patients with relapsed/refractory multiple myeloma
    Lee, Hans C.
    Raje, Noopur S.
    Landgren, Ola
    Upreti, Vijay V.
    Wang, Jin
    Avilion, Ariel A.
    Hu, Xuguang
    Rasmussen, Erik
    Ngarmchamnanrith, Gataree
    Fujii, Hisaki
    Spencer, Andrew
    LEUKEMIA, 2021, 35 (01) : 255 - 258
  • [2] Anti-BCMA antibody-drug conjugate
    Cookson, Emma
    LANCET HAEMATOLOGY, 2021, 8 (01): : E16 - E16
  • [3] Preclinical Evaluation of Hdp-101, a Novel Anti-BCMA Antibody-Drug Conjugate, in Multiple Myeloma
    Ko, Jonathan
    Breunig, Christian
    Figueroa, Vianiuhini
    Lehners, Nicola
    Baumann, Anja
    Palfi, Aniko
    Mueller, Christoph
    Lutz, Christian
    Hechler, Torsten
    Kulke, Michael
    Mueller-Tidow, Carsten
    Goldschmidt, Hartmut
    Pahl, Andreas
    Raab, Marc S.
    BLOOD, 2017, 130
  • [4] Hdp-101, an Anti-BCMA Antibody-Drug Conjugate with a Novel Payload Amanitin in Patients with Relapsed Multiple Myeloma, Initial Findings of the First in Human Study
    Raab, Marc S.
    Kaufman, Jonathan L.
    Richard, Shambavi
    Grosicki, Sebastian
    Takacs, Istvan
    Strassz, Andras
    Pahl, Andreas Martin
    Michael, Thorsten
    Last, Anette
    Szaboki, Hajnalka
    Jentsch, Garrit
    Schoenborn-Kellenberger, Oliver
    Orlowski, Robert Z.
    BLOOD, 2023, 142
  • [5] Hdp-101, an Anti-BCMA Antibody-Drug Conjugate with a Novel Payload Amanitin in Patients with Relapsed Multiple Myeloma, Initial Findings of the First in Human Study
    Kaufman, Jonathan L.
    Orlowski, Robert Z.
    Strassz, Andras
    Pahl, Andreas
    Michaels, Thorsten
    Last, Anette
    Szaboki, Hajnalka
    Jentsch, Garrit
    Schoenborn-Kellenberger, Oliver
    Raab, Marc-Steffen
    BLOOD, 2022, 140 : 7235 - 7236
  • [6] The Anti-BCMA Antibody-Drug Conjugate HDP-101 with a Novel Amanitin Payload Shows Promising Initial First in Human Results in Relapsed Multiple Myeloma
    Raab, Marc-Steffen
    Orlowski, Robert
    Richard, Shambavi
    Grosicki, Sebastian
    Takacs, Istvan
    Strassz, Andras
    Pahl, Andreas
    Kulke, Michael
    Michael, Thorsten
    Last, Anette
    Szaboki, Hajnalka
    Jentsch, Garrit
    Schoenborn-Kellenberger, Oliver
    Kaufman, Jonathan L.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S38 - S38
  • [7] Preclinical evaluation of HDP-101, an anti-BCMA antibody-drug conjugate
    Hechler, Torsten
    Palfi, Aniko
    Mueller, Christoph
    Lutz, Christian
    Pahl, Andreas
    Kulke, Michael
    CANCER RESEARCH, 2017, 77
  • [8] Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma
    Stewart, A. Keith
    Krishnan, Amrita Y.
    Singhal, Seema
    Boccia, Ralph V.
    Patel, Manish R.
    Niesvizky, Ruben
    Chanan-Khan, Asher A.
    Ailawadhi, Sikander
    Brumm, Jochen
    Mundt, Kirsten E.
    Hong, Kyu
    McBride, Jacqueline
    Quyen Shon-Nguyen
    Xiao, Yuanyuan
    Ramakrishnan, Vanitha
    Polson, Andrew G.
    Samineni, Divya
    Leipold, Douglas
    Humke, Eric W.
    McClellan, James Scott
    Berdeja, Jesus G.
    BLOOD CANCER JOURNAL, 2019, 9 (2)
  • [9] Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma
    A. Keith Stewart
    Amrita Y. Krishnan
    Seema Singhal
    Ralph V. Boccia
    Manish R. Patel
    Ruben Niesvizky
    Asher A. Chanan-Khan
    Sikander Ailawadhi
    Jochen Brumm
    Kirsten E. Mundt
    Kyu Hong
    Jacqueline McBride
    Quyen Shon-Nguyen
    Yuanyuan Xiao
    Vanitha Ramakrishnan
    Andrew G. Polson
    Divya Samineni
    Douglas Leipold
    Eric W. Humke
    James Scott McClellan
    Jesus G. Berdeja
    Blood Cancer Journal, 9
  • [10] The anti-BCMA antibody-drug conjugate HDP-101 with a novel amanitin payload shows promising initial first in human results in relapsed multiple myeloma
    Kaufman, Jonathan
    Raab, Marc
    Richard, Shambavi
    Grosicki, Sebastian
    Takacs, Istvan
    Strassz, Andras
    Pahl, Andreas
    Kulke, Michael
    Michael, Thorsten
    Last, Anette
    Szaboki, Hajnalka
    Jentsch, Garrit
    Schonborn-Kellenberger, Oliver
    Orlowski, Robert
    CANCER RESEARCH, 2024, 84 (07)
12345